We recently compiled a list of the 10 Worst ARK Stocks To Buy According To Short Sellers. In this article, we are going to take a look at where Teladoc Health, Inc. (NYSE:TDOC) stands against the other ARK stocks.

Investing comes in all sizes and flavors. For the risk averse investors that are looking for steady payouts or long term stability, value and dividend paying stocks are the way to go. For others, that are looking for serious returns, growth stocks are preferred at the cost of higher risk.

One hedge fund that takes a pure play aggressive growth stock investment approach is Cathie Wood’s ARK Investment. Ark is known for investing in stocks that it believes are or will prove to be disruptive. This strategy has seen the firm’s returns somewhat tailored to the broader economic and stock market environment. For instance, during the coronavirus pandemic when interest rates were at historic lows and internet stocks were booming, Ark Investment returned 20% in 2020. This led to Wood giving an interview with Bloomberg where she stressed that her firm kept a multi year investment horizon in mind when buying stocks. She also shared that Ark’s investment approach was thematic in nature, and as opposed to big tech stocks that had reaped most of their returns already, the hedge fund was focusing on sectors that it believed held the most promising futures. Some of the sectors that were on her mind were DNA companies, robotics, blockchain, energy storage, and everyone’s favorite, artificial intelligence.

While we’ll get to the other end of Wood’s returns being tailored to the economy or the broader stock market, artificial intelligence brings another controversial decision that her firm has made to our mind. This was when her firm decided to completely exit Wall Street’s favorite artificial intelligence stock, which ranks 14th on our list of Morgan Stanley’s Highest Conviction Stocks: Top 20 Stocks To Buy and is a multi trillion dollar firm known for its AI GPUs. What do Wood and this stock have in common? Well, her fund cut its stake in the firm by 63% in Q4 2022. Back then, the shares were trading at a post split valuation of $14.61 or at $146 pre split. By June 2024, the stock had soared to $1,131 (pre split) meaning that Ark had missed out on a whopping $854 million in gains.

Commenting on her decision later on, she shared that “we also redeployed a, a good chunk of” the proceeds from the stock sales, “certainly at the later stage of our selling” into the fast growth stock that’s ranked 6th in our list of the 10 Best Fast Growth Stocks To Buy Now. This stock “last year was actually up more” than the GPU company, said Wood, adding that if the GPU stock is “to continue working, we must see this pull through into more of the tech stack. Otherwise, we have some productivity tools and, uh, assistants, that are working at the periphery of organizations but are not getting at, uh, what Dario, the CEO of Anthropic, calls the central part of organizations.”

As to buying the shares again, Wood hasn’t ruled out buying it back again, she will only make such a decision “if there were a significant price correction around, around, let’s say around an inventory” correction. The investor then shared examples of historic inventory corrections especially when the cryptocurrency market underwent this correction and a glut led to the stock dropping by “two thirds in one quarter.”

Cycling back, the stock market’s recent performance has also made an impact on Wood’s portfolio. Looking at the performance of her top ten stock picks during Q4 2020 and analyzing their gains or losses by the close of Q1 2024, only four stocks remained in her portfolio. By the close of H1 2024, these stocks were all in the red. The worst performer amongst them had lost 86% since the start of 2021, while the others’ losses ranged between 73% to 39%. If you’re hoping that the stocks that were eliminated might have fared better, you’d be wrong. Not only are all six in the red, but several have lost more than 80% while one has been delisted from the NASDAQ exchange.

This performance would seem to imply that Wood has lost her stock picking mojo. However, this clearly isn’t the case. With the second quarter of 2024 hedge fund filings out, we can see which Cathie Wood stocks have done well and which have faltered. Analyzing the year to date performance of the top ten Cathie Wood stocks shows that six are in the green. This is noticeably better than how her fourth quarter of 2020 stocks have fared since then. These stocks’ performance ranges between 2.21% to 81.42%, with the top three performers up by 46.91%, 64.19%, and 81.42%, respectively. In the same order, these firms belong to software, financial markets, and data analysis industries and they rank 8th, 6th, and 9th in Cathie Wood’s Q2 2024 investment portfolio.

Before we head to our list of the worst Ark stocks to buy when considering short seller sentiment, it’s also important to understand the rationale behind the fund’s picking strategy. In its annual research report, the fund is still bullish on disruptive innovation. It believes that returns generated by firms that are part of this trend could exceed 40% on an annualized basis during the next seven years for a final market cap of $220 trillion. Ark also believes that AI training costs could drop by 75% per year by 2030, and the market for generalizable, or humanoid, robots could cross $24 trillion in annual revenue. Morgan Stanley seems to agree, and you can read more by checking out $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley.

Our Methodology

To make our list of the worst Ark stocks to buy according to short sellers, we ranked 120 stocks out of the 180 present in Ark Invest’s Q2 2024 SEC filings by the percentage of shares outstanding that were sold short and selected the stocks with the highest percentage.

For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Teladoc Health, Inc. (NYSE:TDOC)

Short Interest as % of  Shares Outstanding: 17.06%

Number of Hedge Fund Investors In Q2 2024: 35

Ark Invest’s Q2 2024 Stake: $73.1 million

Teladoc Health, Inc. (NYSE:TDOC) is a digital healthcare services provider that enables patients virtual access to healthcare professionals. It was one of the top performing stocks during the coronavirus pandemic, as lock down mandates coupled with a global healthcare crisis left the market wide open for the company. At 2021’s close, Teladoc Health, Inc. (NYSE:TDOC)’s revenue sat at a whopping $2 billion. However, while it was able to grow its market share during the pandemic, growth has slowed since then as Teladoc Health, Inc. (NYSE:TDOC) expected 2024’s revenue to sit at $2.6 billion at the end of its Q1. This marks flat growth over 2023, which in itself marked a small 8% growth over 2022’s figures. Despite long term tailwinds that could see Teladoc Health, Inc. (NYSE:TDOC) benefit from a growth in America’s elderly population, the firm is continuing to face uncertainty. This was apparent during the Q2 earnings call, where the firm refused to provide guidance for its full year. The key drivers of Teladoc Health, Inc. (NYSE:TDOC)’s hypothesis are its ability to expand its member network, rely on technology to ensure patients are matched with the right physicians, expand the kinds of care offered on its platform, and expand its presence globally.

Teladoc Health, Inc. (NYSE:TDOC)’s management shared some positives during the Q2 2024 earnings call:

“We are continuing to see strength in the number of recruitables that we have, right. The recruitables momentum continues. And I would say, that is testament to our product offerings. The fact that we are seeing strength in selling Chronic Care bundles increasingly. If you think about our overall Chronic Care bookings, more than half of it was Chronic Care bundles. The reason I mention this is, if you think about your question around, how are we doing in converting those recruitables into Chronic Care enrollees, we don’t give the actual number in terms of enrollment, but it continues to be strong and increase relative to what you quoted as the enrollment numbers in the Livongo days.

And the reason for that is, if you think about our ability increasingly to sell Chronic Care bundles to clients, what happens when you do that is, you will see enrollees essentially enroll into multiple conditions, use multiple off our programs rather than say one diabetes program, etc., and all of that helps from an enrollment perspective.”

Overall TDOC ranks 8th on our list of the worst ARK stocks to buy according to short sellers. While we acknowledge the potential of TDOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TDOC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure: None. This article is originally published at Insider Monkey.